Prostate Cancer

Prostate Cancer
2024-11-20T06:46:29.768Z

RADIANT

RADIANT
Prostate cancer

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH)

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate Cancer

Study Phase

III

Trial Identifiers
GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Medical Oncologist

Dr Laurence Krieger

MBChB (Hons) FRACP

Dr Laurence Krieger
location pin icon

North Shore

View Profile
Profile Image - Dr Laurence Krieger

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.